Platinum antitumour agents: a review of (bio)analysis.

Platinum antitumour agents: a review of (bio)analysis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Platinum antitumour agents: a review of (bio)analysis. Abstract Text:

This paper summarizes analytical techniques in order to get a clear picture of the ins and outs of the (bio)analysis of platinum-containing compounds. The antitumour agent cisplatin has become an indispensable drug for the cure of a variety of cancer diseases. Since its introduction in the early seventies, about 2,000 related platinum complexes were designed to devoid the dose-limiting nephrotoxicity. Some of them were introduced for clinical trial, such as carboplatin and iproplatin. To investigate the mechanism of action and pharmaco-kinetic behaviour, several interesting assays for total and specific platinum determination in biological matrices have been developed, each with its own possibilities and limitations.

Platinum antitumour agents: a review of (bio)analysis. Publishing Authors By Initials

For similar investigative techniques: chemistry, analytical: photometry: spectrophotometry research abstracts see: investigative techniques: chemistry, analytical: photometry: spectrophotometry research

PUBMED ID PMID:

MEDLINE DATE:

Platinum antitumour agents: a review of (bio)analysis. Journal Published:

PUBLICATION TYPE: Review

Journal: Pharmaceutisch weekblad. Scientific edition

VOLUME: 14

Page Numbers: 61-77

Journal Abbreviation:

ISSN: 0167-6555

DAY: 19

MONTH: Jun

YEAR: 1992

Platinum antitumour agents: a review of (bio)analysis. Information

Number of References: 188

LANGUAGE: eng

NlmUniqueID: 7907992

Platinum antitumour agents: a review of (bio)analysis. Keywords Mesh Terms:

KEYWORDS: Spectrophotometry

MESH TERMS: analysis

Chemical & Substance for Abstract: Platinum antitumour agents: a review of (bio)analysis. Information

Substance Name: Platinum

Registry Number: 7440-06-4

Grant and Affiliation Information for Platinum antitumour agents: a review of (bio)analysis.

AFFILIATION: Department of Pharmaceutical Analysis, Faculty of Pharmacy, State University of Utrecht, The Netherlands.

Country: NETHERLANDS

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Pharm Weekbl Sci

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Platinum antitumour agents: a review of bioanalysis Related Publications

• A sensitive assay for the quantitative analysis of vinorelbine in mouse and human EDTA plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry.
• Amyloid Beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.
• Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.
• Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens.
• Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling.
• Development and validation of an assay for the quantitative determination of cladribine nucleotides in MDCKII cells and culture medium using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry.
• Didanosine, a new antiretroviral drug. A review.
• Dideoxynucleoside therapy for HIV infection.
• Drug Interaction of Fluvoxamine and Fluoxetine with Nevirapine in HIV-1-Infected Individuals.
• Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance.
• Enhanced resolution triple-quadrupole mass spectrometry for ultra-sensitive and quantitative analysis of the investigational anticancer agent EO9 (apaziquone) and its metabolite EO5a in human and dog plasma to support (pre)-clinical studies of EOquin(R) g
• Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care.
• Home-based chemotherapy confronts pharmacists with stability and compatibility problems.
• Liquid chromatography-tandem mass spectrometric assay for diclofenac and three primary metabolites in mouse plasma.
• Liquid chromatography-tandem mass spectrometric assays for salinomycin in mouse plasma, liver, brain and small intestinal contents and in OptiMEM cell culture medium.
• Liquid chromatography/tandem mass spectrometric method for the quantification of eight proteolytic fragments of ITIH(4) with biomarker potential in human plasma and serum.
• New cytotoxic drugs and targets in oncology.
• Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature.
• Platinum antitumour agents: a review of (bio)analysis.
• Prescription error resulting in valproic acid intoxication.
• Quantitative and selective assay of 5-methylindirubine, an inhibitor of cyclin-dependent kinases, in murine plasma using coupled liquid chromatography and electrospray tandem mass spectrometry.
• Quantitative aspects of the analysis of the monoclonal antibody trastuzumab using high-performance liquid chromatography coupled with electrospray mass spectrometry.
• Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry.
• Serum Amyloid Beta Peptides in Patients with Dementia and Age-Matched Non-Demented Controls as Detected by Surface-Enhanced Laser Desorption Ionisation-Time of Flight Mass Spectrometry (SELDI-TOF MS).
• The risks of handling cytotoxic drugs. I. Methods of testing exposure.
• The risks of handling cytotoxic drugs. II. Recommendations for working with cytotoxic drugs.